Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Thompson, A; Sorensen, PS; Montalban, X; Cook, S; Goodkin, D; Filippi, M; Kappos, L; Cohen, J; Ebers, G; Cutter, G; Fazekas, F; Barkhof, F; Miller, A; Brooks, BR; Noseworthy, J; Lucchinetti, C; Weinshenker, B.
Overview of European pilot study of interferon beta-1b in primary progressive multiple sclerosis - Question and answer session.
MULT SCLER. 2004; 10 Suppl 1(1): S62; discussion 62-S62; discussion 64. Doi: 10.1191/1352458504ms1033oa
Web of Science PubMed FullText FullText_MUG

 

Co-Autor*innen der Med Uni Graz
Fazekas Franz
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
This short monograph describes a trial of interferon beta-1b in patients with primary progressive multiple sclerosis (PPMS) or transitional MS. Designed as a randomized, placebo-controlled pilot, the trial randomly placed 73 eligible patients into two groups, placebo or interferon beta-1b 8 MIU given subcutaneously every other day for two years. Significant differences favouring interferon beta-1b in the MSFC score, T2 lesion volume and TI lesion volume at 24 months were observed. Further study of interferon beta-Ib therapy in PPMS patients in warranted.
Find related publications in this database (using NLM MeSH Indexing)
Adjuvants, Immunologic - therapeutic use
Europe - therapeutic use
Humans - therapeutic use
Interferon-beta - therapeutic use
Multiple Sclerosis, Chronic Progressive - drug therapy
Pilot Projects - drug therapy

© Med Uni Graz • Impressum